1. Home
  2. XEL vs ALNY Comparison

XEL vs ALNY Comparison

Compare XEL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Energy Inc.

XEL

Xcel Energy Inc.

HOLD

Current Price

$80.41

Market Cap

49.2B

Sector

Utilities

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$330.95

Market Cap

42.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XEL
ALNY
Founded
1909
2002
Country
United States
United States
Employees
N/A
115
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.2B
42.1B
IPO Year
2003
2004

Fundamental Metrics

Financial Performance
Metric
XEL
ALNY
Price
$80.41
$330.95
Analyst Decision
Buy
Strong Buy
Analyst Count
13
28
Target Price
$84.92
$471.93
AVG Volume (30 Days)
3.8M
1.0M
Earning Date
04-30-2026
04-30-2026
Dividend Yield
2.82%
N/A
EPS Growth
N/A
206.88
EPS
3.42
2.33
Revenue
$11,537,000,000.00
$1,037,418,000.00
Revenue This Year
$10.01
$52.99
Revenue Next Year
$8.05
$31.77
P/E Ratio
$23.61
$136.85
Revenue Growth
N/A
22.88
52 Week Low
$65.21
$205.87
52 Week High
$84.23
$495.55

Technical Indicators

Market Signals
Indicator
XEL
ALNY
Relative Strength Index (RSI) 54.06 53.95
Support Level $78.43 $302.52
Resistance Level $82.54 $345.90
Average True Range (ATR) 1.49 10.99
MACD 0.10 2.36
Stochastic Oscillator 65.73 86.12

Price Performance

Historical Comparison
XEL
ALNY

About XEL Xcel Energy Inc.

Xcel Energy manages utilities serving 3.9 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: